MCID: CRN030
MIFTS: 50

Coronary Stenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Coronary Stenosis

MalaCards integrated aliases for Coronary Stenosis:

Name: Coronary Stenosis 12 54 43 15 17 71
Coronary Artery Stenosis 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:4248
MeSH 43 D023921
NCIt 49 C80427
UMLS 71 C0242231

Summaries for Coronary Stenosis

MalaCards based summary : Coronary Stenosis, also known as coronary artery stenosis, is related to kawasaki disease and angina pectoris, and has symptoms including angina pectoris An important gene associated with Coronary Stenosis is APOA1 (Apolipoprotein A1), and among its related pathways/superpathways are Lipoprotein metabolism and Metabolism of fat-soluble vitamins. The drugs Isosorbide Dinitrate and AT-101 have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Related Diseases for Coronary Stenosis

Diseases related to Coronary Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 kawasaki disease 30.9 NPPB IL6 CRP ALB
2 angina pectoris 30.8 TNNI3 PIK3C2A NPPB IL6 CRP APOA1
3 coronary artery vasospasm 30.8 TNNI3 PIK3C2A CRP ACE
4 right bundle branch block 30.8 TNNI3 NPPB ACE
5 chlamydia 30.8 TLR4 IL6 CRP
6 anterolateral myocardial infarction 30.7 NPPB ACE
7 syphilis 30.7 CRP ALB ACE
8 ischemia 30.6 PON1 PIK3C2A NPPB ICAM1 CXCL12 ACE
9 ischemic colitis 30.6 SERPINE1 CRP ACE
10 subendocardial myocardial infarction 30.6 SERPINE1 PIK3C2A
11 atrioventricular block 30.6 TNNI3 PIK3C2A NPPB ACE
12 aortic aneurysm 30.6 IL6 CRP APOE ACE
13 rheumatic heart disease 30.5 NPPB IL6 ACE
14 aortic disease 30.5 IL6 CRP APOE ACE
15 cardiogenic shock 30.5 NPPB IL6 CRP
16 infective endocarditis 30.5 TNNI3 SERPINE1 IL6 CRP
17 carotid stenosis 30.4 ICAM1 CRP APOE ACE
18 chlamydia pneumonia 30.4 TLR4 IL6 CRP APOE
19 atrial heart septal defect 30.4 TNNI3 NPPB CRP ALB ACE
20 mitral valve disease 30.4 TNNI3 NPPB CRP ACE
21 hyperlipoproteinemia, type iii 30.4 LPL CETP APOE APOB APOA1
22 endocarditis 30.4 TNNI3 SERPINE1 PIK3C2A IL6 CRP ALB
23 aortic aneurysm, familial abdominal, 1 30.4 IL6 CRP CETP APOE ACE
24 thrombocytosis 30.4 VWF IL6 CRP ALB
25 vasculitis 30.4 VWF IL6 ICAM1 CRP
26 essential thrombocythemia 30.3 VWF SERPINE1 IL6 CRP
27 periodontitis 30.3 TLR4 IL6 ICAM1 CRP
28 mitral valve insufficiency 30.3 TNNI3 NPPB CRP ALB ACE
29 plague 30.2 TLR4 IL6 ALB
30 migraine with or without aura 1 30.2 IL6 CRP ALB ACE
31 left bundle branch hemiblock 30.2 TNNI3 PIK3C2A NPPB CRP ACE
32 cardiac arrest 30.2 PIK3C2A NPPB ICAM1 APOE ALB ACE
33 antiphospholipid syndrome 30.2 VWF SERPINE1 PON1 CRP
34 takayasu arteritis 30.2 VWF IL6 ICAM1 CRP
35 acute myocarditis 30.1 TNNI3 NPPB IL6 CRP ACE
36 connective tissue disease 30.1 TLR4 IL6 CRP ALB ACE
37 crohn's disease 30.1 TLR4 IL6 CRP ALB
38 aortic valve insufficiency 30.0 VWF PON1 NPPB CRP ALB ACE
39 congestive heart failure 30.0 TNNI3 PIK3C2A NPPB IL6 CRP ALB
40 homocysteinemia 30.0 VWF SERPINE1 PON1 CRP APOE ALB
41 ulcerative colitis 30.0 TLR4 IL6 ICAM1 CRP
42 proteasome-associated autoinflammatory syndrome 1 29.9 TLR4 IL6 ICAM1 CRP ALB
43 pericarditis 29.9 TNNI3 NPPB IL6 CRP ALB ACE
44 heart valve disease 29.8 VWF TNNI3 NPPB CRP ALB ACE
45 pulmonary hypertension 29.8 VWF SERPINE1 NPPB IL6 CRP ALB
46 pulmonary embolism 29.8 VWF TNNI3 SERPINE1 NPPB CRP ALB
47 pulmonary fibrosis, idiopathic 29.8 TLR4 SERPINE1 IL6 CXCL12 CRP ALB
48 patent foramen ovale 29.8 VWF TNNI3 SERPINE1 NPPB CRP ALB
49 aortic atherosclerosis 29.7 TLR4 PON1 LPL CETP APOE ACE
50 pulmonary disease, chronic obstructive 29.7 TLR4 NPPB IL6 CRP ALB ACE

Graphical network of the top 20 diseases related to Coronary Stenosis:



Diseases related to Coronary Stenosis

Symptoms & Phenotypes for Coronary Stenosis

UMLS symptoms related to Coronary Stenosis:


angina pectoris

GenomeRNAi Phenotypes related to Coronary Stenosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.5 APOA1 APOB APOE CETP CXCL12 LPL
2 Increased LDL uptake GR00340-A-1 8.92 APOA1 APOE CXCL12 LPL

MGI Mouse Phenotypes related to Coronary Stenosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 ACE ALB APOA1 APOB APOE CRP
2 homeostasis/metabolism MP:0005376 10.22 ACE ALB APOA1 APOB APOE CRP
3 cellular MP:0005384 10.15 ALB APOA1 APOB APOE CXCL12 ICAM1
4 immune system MP:0005387 10.07 ACE ALB APOB APOE CRP CXCL12
5 adipose tissue MP:0005375 9.98 ACE APOE IL6 LPL PIK3C2A SERPINE1
6 liver/biliary system MP:0005370 9.93 ACE ALB APOA1 APOB APOE CXCL12
7 mortality/aging MP:0010768 9.8 ACE ALB APOB APOE CXCL12 ICAM1
8 muscle MP:0005369 9.32 ALB APOB APOE CXCL12 ICAM1 IL6

Drugs & Therapeutics for Coronary Stenosis

Drugs for Coronary Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
2
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
3
Nitric Oxide Approved Phase 4 10102-43-9 145068
4
Glucagon Approved Phase 4 16941-32-5
5
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
6
Liraglutide Approved Phase 4 204656-20-2 44147092
7
Iodine Approved, Investigational Phase 4 7553-56-2 807
8
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
9
Eplerenone Approved Phase 4 107724-20-9 150310 443872
10
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
11 Orange Approved Phase 4
12
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
13
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
14
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Adenosine Approved, Investigational Phase 4 58-61-7 60961
17
Edoxaban Approved Phase 4 480449-70-5
18
Fenofibrate Approved Phase 4 49562-28-9 3339
19
Atorvastatin Approved Phase 4 134523-00-5 60823
20
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
21
Ticagrelor Approved Phase 4 274693-27-5 9871419
22
Cangrelor Approved Phase 4 163706-06-7 9854012
23
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
24
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
25
Candesartan Experimental Phase 4 139481-59-7 2541
26 Incretins Phase 4
27 Chlorhexidine gluconate Phase 4
28 Disinfectants Phase 4
29 Anti-Infective Agents, Local Phase 4
30 Natriuretic Agents Phase 4
31 isosorbide-5-mononitrate Phase 4
32 diuretics Phase 4
33 Nitric Oxide Donors Phase 4
34 HIV Protease Inhibitors Phase 4
35
protease inhibitors Phase 4
36 Protective Agents Phase 4
37 Glucagon-Like Peptide 1 Phase 4
38 Hypoglycemic Agents Phase 4
39 Antihypertensive Agents Phase 4
40 cadexomer iodine Phase 4
41 Angiotensin-Converting Enzyme Inhibitors Phase 4
42 Mineralocorticoids Phase 4
43 Mineralocorticoid Receptor Antagonists Phase 4
44 Diuretics, Potassium Sparing Phase 4
45 Calamus Phase 4
46 carnitine Phase 4
47 Alpha-lipoic Acid Phase 4
48 Thioctic Acid Phase 4
49 Antioxidants Phase 4
50 Angiotensinogen Phase 4

Interventional clinical trials:

(show top 50) (show all 495)
# Name Status NCT ID Phase Drugs
1 Comparison of Fractional Flow Reserve and Minimal Luminal Area by Intravascular Ultrasound in Evaluating Intermediate Coronary Artery Stenosis in Each Coronary Artery Unknown status NCT01133015 Phase 4
2 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
3 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
4 Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions) Unknown status NCT01278186 Phase 4
5 A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Completed NCT01137786 Phase 4 Non ionic contrast media comparator;Non ionic contrast media comparator
6 A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Completed NCT01136876 Phase 4 Iopamidol;Iodixanol-320
7 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
8 A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis Completed NCT01513070 Phase 4 Quick-Acting Heart Reliever;Isosorbide Dinitrate;Placebo of Isosorbide Dinitrate;Aspirin Enteric-coated Tablets;Placebo of Quick-Acting Heart Reliever;Aspirin Enteric-coated Tablets
9 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (X-ACT Study) Completed NCT01255722 Phase 4 iobitridol;iopromide;iomeprol
10 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
11 EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease. Completed NCT00531011 Phase 4
12 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
13 Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients Completed NCT01490398 Phase 4 Rosuvastatin
14 Prospective Randomized Study of Unprotected Left Main Stenting Versus Bypass Surgery Completed NCT00375063 Phase 4
15 Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement Completed NCT01070420 Phase 4
16 A Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients Completed NCT00755443 Phase 4
17 Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels Completed NCT02602600 Phase 4 Liraglutide
18 Excel Drug-Eluting Stent Pilot Clinical Registry Completed NCT00385905 Phase 4
19 Assessment of Coronary Flow Reserve and CT Angiography By Hybrid PET/CT: Relation to Clinically Indicated SPECT Studies Completed NCT00320931 Phase 4
20 Differential Effect of Ticagrelor vs Prasugrel or Clopidogrel Loading on Fractional Flow Reserve Completed NCT02108808 Phase 4 Ticagrelor;Prasugrel or Clopidogrel
21 A Double-Blind, Multicenter, Placebo Controlled Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease. Completed NCT00150826 Phase 4 Quinapril;Placebo
22 Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions Completed NCT00693251 Phase 4
23 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT00402272 Phase 4
24 (RTMPE for CAV) Real Time Myocardial Perfusion Echocardiography for Detection of Coronary Allograft Vasculopathy in Cardiac Transplant Patients Completed NCT02880137 Phase 4 Perflutren Lipid Microsphere
25 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT01171820 Phase 4
26 Model Project for the Reduction of Coronary Restenosis Completed NCT00627900 Phase 4
27 Vision II: Non Randomized French Evaluation of GALILEO Intravascular Radiotherapy System in Patients With de Novo Coronary Arteries Lesions by Restenosis on Angioplasty or Restenosis on Endoprosthesis Completed NCT00180583 Phase 4
28 A Double-Blind, Multicenter, Placebo Controlled Study of Aldosterone Blockade (Eplerenone) in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease Completed NCT00187889 Phase 4 Eplerenone;Placebo or sugar pill
29 Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson Completed NCT01779869 Phase 4 Regadenoson
30 Comparison of the Efficacy and Safety of Paclitaxel-Eluting CoroflexTM Please Stent Versus Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease Completed NCT00995423 Phase 4
31 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4
32 Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies. Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
33 Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain Completed NCT01067456 Phase 4
34 Contrast Enhancement on Coronary Computed Tomographic Angiography : Effects on Intra-Coronary Attenuation Using Low Iodine Concentrations While Maintaining Identical IDR (EICAR-Trial) Completed NCT02462044 Phase 4 240 mg Iodine;300 mg Iodine;370 mg Iodine
35 A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation Completed NCT02140801 Phase 4 Ticagrelor;Clopidogrel
36 Randomized Comparison of Everolimus- Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus Completed NCT00997763 Phase 4
37 Randomized Comparison of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus Completed NCT01186107 Phase 4
38 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
39 Evaluation of Endothelial Progenitor Cell (EPC) Capturing (GENOUS) Stent After Coronary Stenting Utilizing Optical Coherence Tomography (OCT): the EGO Study Completed NCT01272895 Phase 4
40 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
41 Phase 4 Study of Pioglitazone on Neointima Volume and Inflammatory Markers in Diabetic Patients Completed NCT00494559 Phase 4 Pioglitazone;Placebo
42 Fractional Flow Reserve - Guided Elective Coronary Angioplasty Using Paclitaxel - Eluting Balloons With Provisional Stent Implantation: A Phase 4 Feasibility Study With 6-Month Follow-up by Optical Coherence Tomography Completed NCT02120859 Phase 4
43 Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation Completed NCT00139386 Phase 4 Candesartan
44 Endothelial Stent Coverage and Neointimal Proliferation at 6 Months After Implantation of a Coronary Everolimus-Eluting Stent Compared With a Bare Metal Stent Postdilated With a Paclitaxel-Eluting Balloon: A Randomised Study Using Optical Coherence Tomography Completed NCT01056744 Phase 4
45 XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT) Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
46 Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth. A Clinical, Multi-center, Prospective, Non-Randomized Study Completed NCT00349895 Phase 4
47 SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT00697372 Phase 4
48 Comparison of the Efficacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions Completed NCT00418067 Phase 4
49 Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT01200693 Phase 4
50 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial Completed NCT02577965 Phase 4

Search NIH Clinical Center for Coronary Stenosis

Cochrane evidence based reviews: coronary stenosis

Genetic Tests for Coronary Stenosis

Anatomical Context for Coronary Stenosis

MalaCards organs/tissues related to Coronary Stenosis:

40
Heart, Testes, Endothelial, Kidney, Liver, Neutrophil, Lung

Publications for Coronary Stenosis

Articles related to Coronary Stenosis:

(show top 50) (show all 8289)
# Title Authors PMID Year
1
The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease. 54 61
19551315 2009
2
[Lipoprotein (a), D-Dimer and apolipoprotein A1 as markers of presence and severity of coronary disease]. 54 61
19386322 2009
3
Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. 61 54
18403458 2008
4
[Level of alpha-granule membrane protein (CD62P) in coronary heart disease]. 61 54
18353216 2008
5
[Association between plasma adiponectin levels and coronary lesion complexity]. 61 54
18087549 2007
6
[Predictive value of lipoprotein (a) and apolipoprotein A1 in patients with angiographycally evaluated coronary stenosis]. 61 54
17524316 2007
7
The 3'-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. 61 54
16829343 2006
8
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. 61 54
16084515 2006
9
Cholesteryl ester transfer protein gene polymorphisms and severity of coronary stenosis. 54 61
16553359 2006
10
Association of Leu125Val polymorphism of platelet endothelial cell adhesion molecule-1 (PECAM-1) gene & soluble level of PECAM-1 with coronary artery disease in Asian Indians. 61 54
15756041 2005
11
R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. 61 54
15488875 2004
12
Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFRII in patients with coronary artery disease. 61 54
15495786 2004
13
Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFalphaRII in patients with coronary artery disease. 54 61
14603993 2003
14
[Lipoprotein (a)--a mysterious factor in atherogenesis]. 54 61
12679978 2002
15
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. 61 54
11171785 2001
16
Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. 61 54
10487496 1999
17
Plasma lipids, lipoproteins and apolipoproteins and sudden cardiac death. 61 54
10335875 1999
18
Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. 61 54
9242969 1997
19
Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. 54 61
8960946 1996
20
Characteristics of vasospastic angina with exercised-induced ischemia--analysis of parameters of hemostasis and fibrinolysis. 61 54
8803721 1996
21
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. 61 54
7686453 1993
22
Ischemia and No Obstructive Stenosis (INOCA) at CT Angiography, CT Myocardial Perfusion, Invasive Coronary Angiography, and SPECT: The CORE320 Study. 61
31746688 2020
23
Reduced regional strain rate is the most accurate dysfunction in predicting culprit lesions in patients with acute coronary syndrome. 61
31549763 2020
24
Deferral Versus Performance of Revascularization for Coronary Stenosis With Grey Zone Fractional Flow Reserve Values: A Systematic Review and Meta-Analysis. 61
31315429 2020
25
Correlation of cathepsin S with coronary stenosis degree, carotid thickness, blood pressure, glucose and lipid metabolism and vascular endothelial function in atherosclerosis. 61
31853273 2020
26
Coronary artery to aortic luminal attenuation ratio in coronary CT angiography for the diagnosis of haemodynamically significant coronary artery stenosis. 61
31738082 2020
27
Clinical and angiographic factors predicting fractional flow reserve and explaining the visual-functional mismatch in patients with intermediate coronary artery stenosis. 61
31609758 2020
28
Coronary artery aneurysms, insights from the international coronary artery aneurysm registry (CAAR). 61
31378382 2020
29
Haemodynamics Study of Tapered Stents Intervention to Tapered Arteries. 61
31617078 2019
30
Mapping and Ablation of Arrhythmias from Uncommon Sites (Aortic Cusp, Pulmonary Artery, and Left Ventricular Summit). 61
31706473 2019
31
Evaluation of Chronic Total Occlusion Recanalization: A Physiologic Assessment Perspective by Dynamic Exercise Tests. 61
31786530 2019
32
Diagnosis of coronary artery disease in patients with atrial fibrillation using low tube voltage coronary CT angiography with isotonic low-concentration contrast agent. 61
31363878 2019
33
The validity and applicability of CAD-RADS in the management of patients with coronary artery disease. 61
31802266 2019
34
Dysregulated expression of STAT1, miR-150, and miR-223 in peripheral blood mononuclear cells of coronary artery disease patients with significant or insignificant stenosis. 61
31318097 2019
35
Cardiac CT: why, when, and how : Update 2019. 61
31062037 2019
36
Biomarkers and their relative contributions to identifying coronary artery stenosis based on coronary computed tomography angiography in asymptomatic adults. 61
31520588 2019
37
Precise measurement of coronary stenosis diameter with CCTA using CT number calibration. 61
31603567 2019
38
Machine Learning for Pretest Probability of Obstructive Coronary Stenosis in Symptomatic Patients. 61
31734209 2019
39
The early repolarization pattern and gated SPECT abnormality at coronary stenosis. 61
30507353 2019
40
An old friend: uric acid and its association with fractional flow reserve 61
31655503 2019
41
Identification of a blood-based 12-gene signature that predicts the severity of coronary artery stenosis: An integrative approach based on gene network construction, Support Vector Machine algorithm, and multi-cohort validation. 61
31689620 2019
42
Spontaneous coronary artery spasm detected by computed tomography coronary angiography: Provoked spasm site similar to intracoronary injection of ergonovine but not acetylcholine. 61
31762835 2019
43
Does vessel length impact transluminal attenuation gradient in 320-slice coronary CT angiography? Correlation with invasive angiography. 61
31264012 2019
44
Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses: A Multicenter Study Using Intracoronary Pressure and Flow. 61
31752515 2019
45
Ranolazine May Exert its Beneficial Effects by Increasing Myocardial Adenosine Levels. 61
31834840 2019
46
Study of functional drug-eluting stent in promoting endothelialization and antiproliferation. 61
31626738 2019
47
Coronary Functional Abnormalities in Patients With Angina and Nonobstructive Coronary Artery Disease. 61
31699275 2019
48
Association between new circulating proinflammatory and anti-inflammatory adipocytokines with coronary artery disease. 61
31464731 2019
49
Mechanisms of Myocardial Infarction in Patients With Nonobstructive Coronary Artery Disease: Results From the Optical Coherence Tomography Study. 61
30343070 2019
50
Pre-test probability prediction in patients with a low to intermediate probability of coronary artery disease: a prospective study with a fractional flow reserve endpoint. 61
31083725 2019

Variations for Coronary Stenosis

Expression for Coronary Stenosis

Search GEO for disease gene expression data for Coronary Stenosis.

Pathways for Coronary Stenosis

Pathways related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.29 SCARB1 PCSK9 LPL CETP APOE APOB
2
Show member pathways
12.16 LPL APOE APOB APOA1
3 11.84 TNNI3 APOE APOA1 ALB
4
Show member pathways
11.67 SCARB1 APOE APOB APOA1 ALB
5
Show member pathways
11.61 SERPINE1 SCARB1 IL6 ICAM1 CRP APOE
6 11.59 TLR4 IL6 ICAM1 CXCL12
7
Show member pathways
11.57 SCARB1 PCSK9 LPL CETP APOE APOB
8 11.39 TLR4 IL6 ICAM1
9 11.35 IL6 ICAM1 APOB
10
Show member pathways
11.3 SCARB1 APOB APOA1
11 11.2 IL6 ICAM1 APOA1
12 11.09 TLR4 APOE ACE
13 10.92 SCARB1 APOB APOA1

GO Terms for Coronary Stenosis

Cellular components related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.13 VWF SERPINE1 SCARB1 PON1 PIK3C2A ICAM1
2 cell surface GO:0009986 10.02 TLR4 SCARB1 PCSK9 LPL ICAM1 APOA1
3 collagen-containing extracellular matrix GO:0062023 9.95 VWF SERPINE1 ICAM1 CXCL12 APOE APOA1
4 early endosome GO:0005769 9.91 TLR4 PCSK9 APOE APOB APOA1
5 endoplasmic reticulum lumen GO:0005788 9.91 PCSK9 IL6 APOE APOB APOA1 ALB
6 blood microparticle GO:0072562 9.84 PON1 APOE APOA1 ALB
7 extracellular region GO:0005576 9.83 VWF SERPINE1 PON1 PCSK9 NPPB LPL
8 platelet alpha granule lumen GO:0031093 9.73 VWF SERPINE1 ALB
9 endocytic vesicle lumen GO:0071682 9.67 APOE APOB APOA1
10 very-low-density lipoprotein particle GO:0034361 9.67 LPL APOE APOB APOA1
11 low-density lipoprotein particle GO:0034362 9.63 APOE APOB APOA1
12 intermediate-density lipoprotein particle GO:0034363 9.58 APOE APOB APOA1
13 spherical high-density lipoprotein particle GO:0034366 9.57 PON1 APOA1
14 chylomicron GO:0042627 9.56 LPL APOE APOB APOA1
15 high-density lipoprotein particle GO:0034364 9.55 PON1 CETP APOE APOB APOA1
16 discoidal high-density lipoprotein particle GO:0034365 9.52 APOE APOA1
17 extracellular space GO:0005615 9.5 SERPINE1 PON1 PCSK9 NPPB LPL IL6

Biological processes related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.14 PON1 PCSK9 LPL CETP APOE APOB
2 post-translational protein modification GO:0043687 10.09 PCSK9 IL6 APOE APOB APOA1 ALB
3 receptor-mediated endocytosis GO:0006898 9.99 SCARB1 APOE APOB APOA1 ALB
4 cellular protein metabolic process GO:0044267 9.99 PCSK9 IL6 APOE APOB APOA1 ALB
5 cellular response to lipopolysaccharide GO:0071222 9.97 TLR4 SERPINE1 IL6 ICAM1
6 lipid transport GO:0006869 9.97 SCARB1 CETP APOE APOB APOA1
7 steroid metabolic process GO:0008202 9.95 PCSK9 CETP APOE APOB APOA1
8 platelet degranulation GO:0002576 9.93 VWF SERPINE1 APOA1 ALB
9 retinoid metabolic process GO:0001523 9.91 LPL APOE APOB APOA1
10 phospholipid metabolic process GO:0006644 9.87 PCSK9 LPL APOA1
11 cholesterol metabolic process GO:0008203 9.85 PON1 PCSK9 CETP APOE APOB APOA1
12 phospholipid transport GO:0015914 9.83 SCARB1 CETP APOA1
13 triglyceride metabolic process GO:0006641 9.83 PCSK9 LPL CETP APOE
14 low-density lipoprotein particle clearance GO:0034383 9.8 SCARB1 PCSK9 APOB
15 positive regulation of cholesterol efflux GO:0010875 9.8 PON1 APOE APOA1
16 phosphatidylcholine metabolic process GO:0046470 9.79 PON1 CETP APOA1
17 lipoprotein metabolic process GO:0042157 9.78 PCSK9 APOE APOB APOA1
18 low-density lipoprotein particle remodeling GO:0034374 9.76 CETP APOE APOB
19 cholesterol transport GO:0030301 9.76 SCARB1 CETP APOB APOA1
20 high-density lipoprotein particle clearance GO:0034384 9.75 SCARB1 APOE APOA1
21 chylomicron assembly GO:0034378 9.73 APOE APOB APOA1
22 cholesterol efflux GO:0033344 9.73 SCARB1 APOE APOB APOA1
23 positive regulation of cholesterol storage GO:0010886 9.71 SCARB1 LPL APOB
24 reverse cholesterol transport GO:0043691 9.71 SCARB1 CETP APOE APOA1
25 blood vessel endothelial cell migration GO:0043534 9.69 SCARB1 APOA1
26 chylomicron remnant clearance GO:0034382 9.69 APOE APOB
27 negative regulation of lipid storage GO:0010888 9.68 IL6 CRP
28 positive regulation of cholesterol esterification GO:0010873 9.68 APOE APOA1
29 neutrophil mediated immunity GO:0002446 9.68 IL6 ACE
30 regulation of Cdc42 protein signal transduction GO:0032489 9.68 APOE APOA1
31 cholesterol import GO:0070508 9.67 SCARB1 APOA1
32 very-low-density lipoprotein particle clearance GO:0034447 9.67 APOE APOB
33 lipoprotein biosynthetic process GO:0042158 9.67 APOE APOB APOA1
34 positive regulation of chemokine (C-C motif) ligand 2 secretion GO:1904209 9.66 TLR4 LPL
35 lipoprotein catabolic process GO:0042159 9.66 APOE APOB
36 adhesion of symbiont to host GO:0044406 9.65 SCARB1 ICAM1
37 detection of lipopolysaccharide GO:0032497 9.65 TLR4 SCARB1
38 positive regulation of phospholipid efflux GO:1902995 9.64 APOE APOA1
39 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.64 PCSK9 APOE
40 very-low-density lipoprotein particle remodeling GO:0034372 9.62 LPL CETP APOE APOA1
41 chylomicron remodeling GO:0034371 9.56 LPL APOE APOB APOA1
42 triglyceride homeostasis GO:0070328 9.55 SCARB1 LPL CETP APOE APOA1
43 high-density lipoprotein particle remodeling GO:0034375 9.35 SCARB1 CETP APOE APOA1 ALB
44 cholesterol homeostasis GO:0042632 9.17 SCARB1 PCSK9 LPL CETP APOE APOB

Molecular functions related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.78 PON1 APOE APOB APOA1
2 amyloid-beta binding GO:0001540 9.73 TLR4 SCARB1 APOE APOA1
3 signaling receptor binding GO:0005102 9.7 TLR4 SERPINE1 NPPB LPL CXCL12 APOE
4 apolipoprotein binding GO:0034185 9.58 SCARB1 PCSK9 LPL
5 lipid transporter activity GO:0005319 9.56 CETP APOE APOB APOA1
6 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.54 APOE APOA1
7 low-density lipoprotein particle binding GO:0030169 9.54 SCARB1 PCSK9 CRP
8 lipopolysaccharide receptor activity GO:0001875 9.52 TLR4 SCARB1
9 very-low-density lipoprotein particle receptor binding GO:0070326 9.51 PCSK9 APOE
10 lipoprotein particle binding GO:0071813 9.5 LPL APOE APOA1
11 apolipoprotein receptor binding GO:0034190 9.49 PCSK9 APOA1
12 triglyceride binding GO:0017129 9.46 LPL CETP
13 low-density lipoprotein particle receptor binding GO:0050750 9.26 PCSK9 CRP APOE APOB
14 intermembrane cholesterol transfer activity GO:0120020 8.92 CETP APOE APOB APOA1

Sources for Coronary Stenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....